Compare BAOS & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAOS | GRI |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.3M |
| IPO Year | 2020 | 2020 |
| Metric | BAOS | GRI |
|---|---|---|
| Price | $2.73 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | 9.3K | ★ 34.1K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.98 | $0.18 |
| 52 Week High | $5.40 | $6.70 |
| Indicator | BAOS | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 44.50 |
| Support Level | $2.58 | $2.12 |
| Resistance Level | $2.82 | $2.23 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 43.48 | 51.16 |
Baosheng Media Group Holdings Ltd operates as a V-log streaming marketing service provider. The firm offers comprehensive marketing solutions. Its services are Internet effect marketing, V-log or short video streaming marketing including content production and operation, e-commerce marketing, original data platform system service, and AI technology. It provides one-stop and full-link deep customized marketing solutions for partners. Baosheng Group is also a core agency of domestic Internet companies such as Tencent, Alibaba, Bytedance, and Kuaishou, with performing channel marketing services, technologies, and applications.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.